Nationwide Fund Advisors lifted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 5.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 178,212 shares of the biopharmaceutical company’s stock after acquiring an additional 9,503 shares during the quarter. Nationwide Fund Advisors owned 0.11% of Amicus Therapeutics worth $2,687,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA raised its holdings in shares of Amicus Therapeutics by 3,672.2% in the second quarter. BNP Paribas Arbitrage SA now owns 68,012 shares of the biopharmaceutical company’s stock valued at $685,000 after acquiring an additional 66,209 shares in the last quarter. Alliancebernstein L.P. raised its holdings in shares of Amicus Therapeutics by 16.3% in the second quarter. Alliancebernstein L.P. now owns 205,836 shares of the biopharmaceutical company’s stock valued at $2,073,000 after acquiring an additional 28,800 shares in the last quarter. State of Wisconsin Investment Board bought a new position in Amicus Therapeutics in the second quarter worth about $1,057,000. Bank of Nova Scotia bought a new position in Amicus Therapeutics in the second quarter worth about $1,944,000. Finally, Vanguard Group Inc. raised its holdings in Amicus Therapeutics by 5.0% in the second quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock worth $91,821,000 after purchasing an additional 430,486 shares in the last quarter.
Shares of Amicus Therapeutics, Inc. (NASDAQ FOLD) traded up $0.36 during mid-day trading on Thursday, hitting $15.87. The stock had a trading volume of 2,762,500 shares, compared to its average volume of 2,180,000. Amicus Therapeutics, Inc. has a 1-year low of $5.07 and a 1-year high of $16.60. The stock has a market capitalization of $2,640.00, a price-to-earnings ratio of -8.67 and a beta of 1.72. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The firm had revenue of $10.90 million during the quarter, compared to analysts’ expectations of $9.02 million. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. Amicus Therapeutics’s quarterly revenue was up 419.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.33) EPS. equities analysts expect that Amicus Therapeutics, Inc. will post -1.56 earnings per share for the current year.
In related news, CEO John F. Crowley sold 449,295 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $14.33, for a total value of $6,438,397.35. Following the sale, the chief executive officer now owns 380,723 shares in the company, valued at $5,455,760.59. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Donald J. Hayden, Jr. sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $15.00, for a total value of $300,000.00. Following the completion of the sale, the director now owns 25,814 shares in the company, valued at approximately $387,210. The disclosure for this sale can be found here. In the last quarter, insiders sold 718,920 shares of company stock worth $10,263,669. 3.40% of the stock is owned by insiders.
A number of equities analysts have commented on the stock. BidaskClub downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. Cowen restated a “buy” rating and set a $22.00 price target on shares of Amicus Therapeutics in a research note on Wednesday. Robert W. Baird restated an “outperform” rating and set a $18.00 price target (up previously from $16.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Leerink Swann restated a “buy” rating and set a $20.00 price target (up previously from $17.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Finally, Chardan Capital restated a “buy” rating and set a $18.50 price target (up previously from $16.50) on shares of Amicus Therapeutics in a research note on Thursday, October 5th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $18.31.
TRADEMARK VIOLATION WARNING: This article was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/11/nationwide-fund-advisors-has-2-69-million-position-in-amicus-therapeutics-inc-fold.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.